Frank Grimberg1, Petra Maria Asprion1, Bettina Schneider1, Enkelejda Miho2, Lmar Babrak2, Ali Habbabeh1. 1. Institute of Information Systems, Competence Center Cyber Security and Resilience, School of Business, FHNW University of Applied Sciences and Arts Northwestern Switzerland, Basel, Switzerland. 2. Institute for Medical Engineering and Medical Informatics, School of Life Sciences, FHNW University of Applied Sciences and Arts Northwestern Switzerland, Muttenz, Switzerland.
Abstract
BACKGROUND: The life science industry has a strong interest in real-world data (RWD), a term that is currently being used in many ways and with varying definitions depending on the source. In this review article, we provide a summary overview of the challenges and risks regarding the use of RWD and its translation into real-world evidence and provide a classification and visualization of RWD challenges by means of the RWD Challenges Radar. SUMMARY: Based on a systematic literature search, we identified 3 types of challenges - organizational, technological, and people-based - that must be addressed when deriving evidence from RWD to be used in drug approval and other applications. It further demonstrates that numerous different aspects, for example, related to the application field and the associated industry, must be considered. A key finding in our review is that the regulatory landscape must be carefully assessed before utilizing RWD. KEY MESSAGES: Establishing awareness and insight into the challenges and risks regarding the use of RWD will be key to taking full advantage of the RWD potential. As a result of this review, an "RWD Challenges Radar" will support the establishment of awareness by providing a comprehensive overview of the relevant aspects to be considered when employing RWD.
BACKGROUND: The life science industry has a strong interest in real-world data (RWD), a term that is currently being used in many ways and with varying definitions depending on the source. In this review article, we provide a summary overview of the challenges and risks regarding the use of RWD and its translation into real-world evidence and provide a classification and visualization of RWD challenges by means of the RWD Challenges Radar. SUMMARY: Based on a systematic literature search, we identified 3 types of challenges - organizational, technological, and people-based - that must be addressed when deriving evidence from RWD to be used in drug approval and other applications. It further demonstrates that numerous different aspects, for example, related to the application field and the associated industry, must be considered. A key finding in our review is that the regulatory landscape must be carefully assessed before utilizing RWD. KEY MESSAGES: Establishing awareness and insight into the challenges and risks regarding the use of RWD will be key to taking full advantage of the RWD potential. As a result of this review, an "RWD Challenges Radar" will support the establishment of awareness by providing a comprehensive overview of the relevant aspects to be considered when employing RWD.
Authors: Clementine Nordon; Helene Karcher; Rolf H H Groenwold; Mikkel Zöllner Ankarfeldt; Franz Pichler; Helene Chevrou-Severac; Michel Rossignol; Adeline Abbe; Lucien Abenhaim Journal: Value Health Date: 2015-11-19 Impact factor: 5.725
Authors: Louis P Garrison; Peter J Neumann; Pennifer Erickson; Deborah Marshall; C Daniel Mullins Journal: Value Health Date: 2007 Sep-Oct Impact factor: 5.725
Authors: Hans-Georg Eichler; Eric Abadie; Alasdair Breckenridge; Bruno Flamion; Lars L Gustafsson; Hubert Leufkens; Malcolm Rowland; Christian K Schneider; Brigitte Bloechl-Daum Journal: Nat Rev Drug Discov Date: 2011-07-01 Impact factor: 84.694
Authors: Grace Hampson; Adrian Towse; William B Dreitlein; Chris Henshall; Steven D Pearson Journal: J Comp Eff Res Date: 2018-11-09 Impact factor: 1.744
Authors: John Wise; Angeli Möller; David Christie; Dipak Kalra; Elia Brodsky; Evelina Georgieva; Greg Jones; Ian Smith; Lars Greiffenberg; Marie McCarthy; Michael Arend; Olivier Luttringer; Sebastian Kloss; Steve Arlington Journal: Drug Discov Today Date: 2018-01-11 Impact factor: 7.851